Phase 2 Peripheral Neuropathy Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form
• People who weigh 150 kilograms or less
• People who have been diagnosed with typical CIDP (a nerve condition) by a neurologist who specialises in nerve and muscle diseases, confirmed using recognised 2021 diagnostic guidelines
• People whose CIDP symptoms have previously improved, either partially or fully, with immunoglobulin (IgG) treatment
• People whose CIDP has shown a meaningful worsening within the past 24 months — for example, symptoms got worse when treatment was reduced or stopped, required a higher dose to bring under control, or worsened near the end of a dosing period and then improved after the next dose
• People who are currently on a stable dose of intravenous immunoglobulin (given through a drip), within a specific dose range every 2 to 6 weeks, with no change of more than 10% in dose or frequency in the 3 months before and during the screening period
• People whose disability score on a standard nerve condition scale (called the INCAT score) falls between 0 and 7 at the time of screening

Who may not be able to join:

• People who have been diagnosed with a variant form of CIDP (rather than the typical form), as defined by recognised 2021 guidelines
• People whose nerve condition is caused by something other than CIDP, such as an inherited nerve disease (for example, Charcot-Marie-Tooth disease), an infection (such as Lyme disease), another medical condition (such as lupus, lymphoma, or diabetes-related nerve damage), or exposure to certain drugs, chemicals, or chemotherapy
• People who have another long-term or serious condition affecting the nervous system — such as multiple sclerosis, Parkinson's disease, or stroke — that causes neurological symptoms or could affect how the trial measures CIDP
• People who have taken certain immune-suppressing or immune-modifying medicines (other than intravenous immunoglobulin) for CIDP within the past 3 months or within 5 half-lives of that medicine (whichever is longer), or who have taken certain medicines that affect B-cells (such as rituximab) within the past 6 months — though people on a long-term stable dose of some of these medicines for a condition other than CIDP may still be considered (confirm with trial site)
• People who have had a plasma exchange procedure within the past 3 months
• People with a history of cancer who have not been in complete remission for at least 2 years, or who are currently receiving chemotherapy or radiotherapy — though people with certain treated skin cancers, cervical carcinoma in situ, or stable prostate cancer not needing treatment may still be considered (confirm with trial site)
• People who have had a blood clot in a vein or artery (such as a stroke or pulmonary embolism) within the past 12 months
• People who have a medical condition, abnormal test result, or other health finding that, in the opinion of the trial doctor, could make participation unsafe or interfere with completing the study
• People who have taken part in another clinical trial involving an experimental treatment or device within the past 30 days, or who plan to do so during this trial

Important: Always verify eligibility with the trial site directly before applying.